MiQLab™ for Bioprocessing

With the advancement of technologies such as CRISPR and CAR-T therapies, there has been a significant increase in the development and production of biologic drugs, Advanced Therapeutic Medicinal Products (ATMP) and Cell and Gene Therapies (CGT).

Single-use manufacturing has provided for a large degree of flexibility in terms of production volumes but have also brought about efficiencies in sterility control by reducing hands-on cleaning and sterilization necessary for stainless steel.

However, as much as the industry is working towards completely closed production systems, there remain critical control points that could potentially introduce contamination. Download this report to learn how MiQLab ensures quality and safety with automated, at-line screening for microbial contamination control.